Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Rhea-AI Summary

Silexion Therapeutics (NASDAQ: SLXN) reported third-quarter financial results and began patient treatment in its Phase 2/3 pancreatic cancer trial. Quarterly net loss narrowed to $2.533 million from $3.262 million a year earlier, while nine-month net loss widened to $8.817 million from $7.500 million. Cash was $4.760 million at September 30, 2026, versus $5.991 million at year-end 2025 and $2.2 million at June 30, 2026.

The first SIL204 patient was dosed on September 30 at Tel Aviv Sourasky Medical Center. Silexion expects additional Israeli and German sites to join in the coming months. Preclinical findings supported immune-sensitization and systemic-delivery research. Third-quarter financing generated approximately $2.5 million from a public offering, $0.84 million from warrant inducement and $1.9 million from at-the-market share sales. A 1-for-24 reverse split took effect November 10, 2026.

13 points · 2 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 7 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointAugust public offering raised approximately $2.5 million gross. 1.5× market cap
• Major pointThird-quarter at-the-market share sales raised approximately $1.9 million gross. 1.1× market cap
• Moderate pointSIL204 Phase 2/3 trial began patient treatment at Tel Aviv Sourasky Medical Center on September 30, 2026.
• Moderate pointSeptember warrant inducement transaction raised approximately $0.84 million gross. 50% of market cap
• Moderate pointThird-quarter net loss narrowed to $2.533 million from $3.262 million a year earlier.
• Moderate pointRelated-party promissory note balance fell to zero from $1.568 million at year-end 2025.

7 minor points

• Minor point. Forward-looking: it has not happened yet and may not happen.Additional trial sites in Israel and Germany are expected to join in the coming months.
• Minor pointSIL204 preclinical findings supported an immune-sensitization signature across three immune pathways and four KRAS mutations.
• Minor pointSIL204 research identified natural lipoprotein-mediated uptake into cancer cells, supporting systemic administration.
• Minor pointThird-quarter research and development expenses fell to $1.286 million from $2.157 million a year earlier.
• Minor pointThird-quarter basic and diluted loss per share narrowed to $13.70 from $691.14 a year earlier, split-adjusted.
• Minor pointNine-month basic and diluted loss per share narrowed to $115.56 from $2,486.20 a year earlier, split-adjusted.
• Minor pointShareholders’ equity increased to $2.968 million at September 30, 2026, from $2.603 million at year-end 2025.

Negative

• Major pointOrdinary shares outstanding increased to 603,055 from 13,028 at year-end 2025, both split-adjusted, diluting existing holders.
• Moderate pointNine-month net loss widened to $8.817 million from $7.500 million a year earlier.
• Moderate pointCash of $4.760 million fell from $5.991 million at year-end 2025, but exceeded June 30’s $2.2 million.
• Moderate pointCurrent liabilities rose to $3.681 million at September 30, 2026, from $2.758 million at year-end 2025.
• Minor pointNine-month research and development expenses rose to $4.868 million from $3.765 million during trial ramp-up.

2 minor points

• Minor pointNine-month general and administrative expenses rose to $4.245 million from $3.461 million a year earlier.
• Minor pointThird-quarter general and administrative expenses rose to $1.398 million from $1.135 million a year earlier.

Key Figures

Safety run-in cohort: Approximately 18 patients Randomized cohort: Approximately 166 patients Public offering proceeds: Approximately $2.5 million +5 more

Safety run-in cohort

Approximately 18 patients

Phase 2/3 SIL204 study

Randomized cohort

Approximately 166 patients

Following the safety run-in

Public offering proceeds

Approximately $2.5 million

Gross proceeds; August 2026

Warrant inducement proceeds

Approximately $0.84 million

Gross proceeds; September 2026

At-the-market proceeds

Approximately $1.9 million

Gross proceeds during the third quarter

Cash and cash equivalents

$4.8 million

As of September 30, 2026

Net loss

Approximately $2.5 million

Three months ended September 30, 2026

Net loss

Approximately $8.8 million

Nine months ended September 30, 2026

Previous Earnings Reports

1 past event · Latest: Aug 14

Same Type 1 event

1. Aug 14

   Quarterly results

   24h Move

   -8.7%

   Trial site initiation and screening clearance advanced SIL204 toward patient treatment.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

rna interference, small interfering rna, eus-guided, at-the-market facility, +2 more

6 terms

rna interference medical

"pioneering RNA interference (RNAi) therapies for KRAS-driven cancers"

RNA interference is a natural cellular process that acts like a mute switch to reduce or silence the activity of a specific gene by targeting its messenger RNA, the blueprint used to make a protein. For investors, it matters because therapies and diagnostics that harness this mechanism can precisely block disease-causing proteins, creating new drug classes with high potential reward but also scientific, manufacturing and regulatory risks that affect company value.

small interfering rna medical

"SIL204, a small interfering RNA (siRNA)"

Small interfering RNA (siRNA) are short, lab-made strands of genetic material that act like a mute button inside cells, binding to a specific genetic message and preventing a particular protein from being made. For investors, siRNA represents a drug technology with the potential to treat diseases by precisely turning off harmful genes, which can mean high development costs, regulatory hurdles, intellectual property value, and the possibility of breakthrough therapies that change market dynamics.

eus-guided medical

"direct EUS-guided intratumoral delivery to the primary tumor"

A medical technique in which an ultrasound probe mounted on an endoscope is used to visualize internal organs from inside the digestive tract and guide needles or instruments to a precise spot for diagnosis or treatment. Think of it like using a camera with built‑in sonar to aim a needle without open surgery. For investors, the term indicates demand for specialized devices, procedural adoption, regulatory clearance and reimbursement decisions that can affect revenue and clinical uptake.

at-the-market facility financial

"continued sales under our at-the-market facility"

An at-the-market facility is a standing arrangement that lets a publicly traded company sell new shares directly into the open market at whatever the current market price is, typically through an investment bank acting as a sales agent. For investors it matters because it provides the company with a flexible way to raise cash without a large, one-time share offering; however, selling additional shares can dilute existing ownership and, by increasing supply, may pressure the stock price like adding more tickets to a limited-seat event.

warrant inducement transaction financial

"completed a public offering and a warrant inducement transaction"

A warrant inducement transaction is when a company issues warrants—options to buy shares at a set price—as a sweetener to persuade investors or creditors to approve a deal, restructuring, or other corporate action. Think of it like giving coupons to convince people to agree to a plan; it can speed approvals but may dilute existing shareholders and change potential future share value, so investors watch these carefully.

pharmacokinetic medical

"Pharmacokinetic, cellular uptake kinetics and biodistribution studies are ongoing."

Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

First patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, moving SIL204 into active patient treatment

New translational data expanded SIL204’s profile, including a coordinated immune-sensitization signature across four KRAS mutations and a native lipoprotein-mediated uptake mechanism that supports systemic administration

Third quarter financings increased cash and cash equivalents to $4.8 million and shareholders’ equity to $3.0 million as of September 30, 2026

Grand Cayman, Cayman Islands, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced financial results for the three-month and nine-month periods ended September 30, 2026, and provided a business update.

Ilan Hadar, Chairman and Chief Executive Officer of Silexion, commented: “In the third quarter, we began treating patients with SIL204 in our Phase 2/3 trial in pancreatic cancer. After opening our first clinical site at Tel Aviv Sourasky Medical Center in July, we dosed the first patient at the end of September. At the same time, our laboratory work continued to strengthen the case for SIL204, with new data suggesting it may help the immune system recognize cancer cells, and showing that it uses natural carriers in the blood to enter cancer cells. Our focus now is on enrolling the first group of patients and bringing more hospitals in Israel and Germany into the trial.”

Mirit Horenshtein Hadar, Chief Financial Officer of Silexion, added: “During the third quarter, we completed a public offering and a warrant inducement transaction and continued sales under our at-the-market facility, increasing our cash and cash equivalents to $4.8 million and shareholders’ equity to approximately $3.0 million as of September 30, 2026. This financial progress strengthens our balance sheet and supports the continued advancement of SIL204 as we enroll patients in the Phase 2/3 trial.”

Recent Milestones & Business Highlights

First Patient Dosed in Phase 2/3 Clinical Trial of SIL204: On July 29, 2026, Silexion initiated its Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer (“LAPC”) at Tel Aviv Sourasky Medical Center (“TASMC” or “Ichilov”), and on September 30, 2026, announced that the first patient worldwide had been dosed at TASMC. The prospective, randomized, controlled, multinational, open-label Phase 2/3 study is evaluating SIL204 in combination with standard-of-care chemotherapy, versus chemotherapy alone, in newly diagnosed, treatment-naïve patients with unresectable Stage 3 LAPC whose tumors harbor a confirmed KRAS mutation. SIL204 is administered via a dual-route regimen combining direct EUS-guided intratumoral delivery to the primary tumor with subcutaneous injections designed to provide systemic exposure. The study is structured as an initial safety run-in cohort of approximately 18 patients, followed by expansion into a randomized cohort of approximately 166 patients.

Clinical Site Expansion in Israel and Germany: In Israel, following the approval of the Israeli Ministry of Health, TASMC was activated as the trial’s first clinical site in July 2026, and the first patient was dosed there on September 30, 2026. Additional Israeli oncology centers, alongside leading academic medical institutions in Germany, are progressing through site activation and are expected to join the trial in the coming months.

Expanded Translational Profile of SIL204: In August 2026, Silexion reported preclinical findings showing statistically significant upregulation of FAS (CD95), an immune “death receptor,” and downregulation of HLA-G, an established immune checkpoint, in human KRAS-mutant pancreatic and non-small cell lung cancer cell lines. Together with the MHC-I upregulation reported in May 2026, the findings support a coordinated immune-sensitization signature across three immune pathways and four KRAS mutations (G12D, G12V, G12C and G12R), reinforcing the scientific rationale for combining SIL204 with anti-PD-(L)1 checkpoint inhibitor therapies. In September 2026, the Company reported that SIL204 uses naturally circulating lipoproteins to enter cancer cells and silence mutant KRAS without synthetic transfection reagents or artificial carriers, supporting the systemic administration of SIL204. Pharmacokinetic, cellular uptake kinetics and biodistribution studies are ongoing.

Financing Activities: During the third quarter, Silexion completed a registered public offering in August 2026 with gross proceeds of approximately $2.5 million and a warrant inducement transaction in September 2026 with gross proceeds of approximately $0.84 million, and continued sales of ordinary shares under its at-the-market facility for gross proceeds of approximately $1.9 million. Subsequent to quarter end, on November 10, 2026, the Company effected a 1-for-24 reverse share split.

Financial Results for the Three Months Ended September 30, 2026

Research and development (“R&D”) expenses for the three months ended September 30, 2026, were approximately $1.3 million, compared to approximately $2.2 million for the three months ended September 30, 2025, a decrease of 40.9%.

General and administrative (“G&A”) expenses for the three months ended September 30, 2026, were approximately $1.4 million, compared to approximately $1.1 million for the three months ended September 30, 2025, an increase of 27.3%.

Net loss for the three months ended September 30, 2026, was approximately $2.5 million, compared to approximately $3.3 million for the three months ended September 30, 2025, a decrease of 24.2%.

Financial Results for the Nine Months Ended September 30, 2026

R&D expenses for the nine months ended September 30, 2026, were approximately $4.9 million, compared to approximately $3.8 million for the nine months ended September 30, 2025, an increase of 28.9%. The increase related to the operational ramp-up for the Phase 2/3 clinical trial of SIL204.

G&A expenses for the nine months ended September 30, 2026, were approximately $4.2 million, compared to approximately $3.5 million for the nine months ended September 30, 2025, an increase of 20.0%.

Net loss for the nine months ended September 30, 2026, was approximately $8.8 million, compared to approximately $7.5 million for the nine months ended September 30, 2025, an increase of 17.3%. The increase was mainly due to higher R&D expenses related to the Phase 2/3 clinical trial of SIL204.

Balance Sheet Highlights

• As of September 30, 2026, Silexion had cash and cash equivalents of $4.8 million, compared to $6.0 million as of December 31, 2025, and $2.2 million as of June 30, 2026.
• Total shareholders’ equity was $3.0 million as of September 30, 2026, compared to $2.6 million as of December 31, 2025.

About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers that have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product candidate, which showed a positive trend in comparison to the control of chemotherapy alone, and is now advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), through Phase 2/3 clinical evaluation. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology and further developing its lead product candidate for locally advanced pancreatic cancer. For more information, please visit: https://silexion.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication are forward-looking statements, including, for example, statements regarding the development of SIL204; the conduct, enrollment and timing of the ongoing Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer, including enrollment of the safety run-in cohort and expansion into a randomized cohort; the timing of activation of additional clinical trial sites in Israel and Germany and the potential expansion of the trial into additional jurisdictions; the timing and results of ongoing translational, pharmacokinetic, cellular uptake and biodistribution studies, and the potential to evaluate SIL204 in combination with anti-PD-(L)1 checkpoint inhibitor therapies; the potential therapeutic benefits, mutation coverage, mechanism of action and clinical utility of SIL204 across KRAS-driven cancers; Silexion’s business strategy and development plans; Silexion’s ability to raise additional capital and its future capital requirements, including through its at-the-market facility, public and private offerings, warrant exercises, warrant inducement transactions and other financing arrangements; the outcome of litigation; and Silexion’s ability to restore and maintain compliance with Nasdaq continued listing requirements. These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) the degree of success of Silexion’s ongoing and planned clinical trials, including the Phase 2/3 clinical trial of SIL204, and the risk that early observations may not be predictive of later results; (ii) Silexion’s ability to enroll and treat patients, and to complete the activation of additional clinical sites, on anticipated timelines; (iii) whether Silexion is able to successfully execute upon its strategy and plans via its future operations, and maintain a positive financial position; (iv) the impact of the regulatory environment and compliance complexities; (v) whether Silexion is able to develop future partnerships or other relationships with third parties; (vi) Silexion’s future capital requirements and sources and uses of cash, and the potential impact on the Company’s operations of any inability to secure such capital; (vii) the substantial doubt about the Company’s ability to continue as a going concern described in Note 1(e) to the Company’s unaudited condensed consolidated financial statements for the three-month and nine-month periods ended September 30, 2026; (viii) whether Silexion succeeds at maintaining its Nasdaq listing, including the determination of the Nasdaq hearings panel, compliance with the shareholders’ equity and minimum bid price requirements, and any potential increase to the market value of listed securities requirement; and (ix) other risks and uncertainties set forth in the documents filed by the Company with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 12, 2026. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.

Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
info@silexion.com

Investor Relations
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com

SILEXION THERAPEUTICS CORP
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except share and per share data)

	September 30,	December 31,
	2026	2025
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$4,760	$5,991
Restricted cash	28	27
Prepaid expenses	1,221	570
Other current assets	102	49
TOTAL CURRENT ASSETS	6,111	6,637
NON-CURRENT ASSETS:
Restricted cash	61	57
Long-term deposit and other non-current assets	320	84
Property and equipment, net	21	25
Operating lease right-of-use asset	314	412
TOTAL NON-CURRENT ASSETS	716	578
TOTAL ASSETS	$6,827	$7,215

SILEXION THERAPEUTICS CORP
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (continued)
(U.S. dollars in thousands, except share and per share data)

	September 30,	December 31,
	2026	2025
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Trade payables	$1,244	$787
Current maturities of operating lease liability	196	182
Employee related obligations	460	879
Other account payable	1,781	910
Private warrants to purchase ordinary shares (including $* due to related party, as of September 30, 2026 and December 31, 2025)	*	*
TOTAL CURRENT LIABILITIES	3,681	2,758
NON-CURRENT LIABILITIES:
Long-term operating lease liability	178	286
Related Party Promissory Note	-	1,568
TOTAL NON-CURRENT LIABILITIES	$178	$1,854
TOTAL LIABILITIES	$3,859	$4,612
SHAREHOLDERS’ EQUITY:
Ordinary shares ($3.24 par value per share, 662,500 and 37,500 shares authorized as of September 30, 2026 and December 31, 2025, respectively; 603,055 and 13,028 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively)	1,954	42
Additional paid-in capital	64,997	57,727
Accumulated deficit	(63,983)	(55,166)
TOTAL SHAREHOLDERS’ EQUITY	$2,968	$2,603
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$6,827	$7,215

All share amounts, and par value per share, reflect a 1-for-10 reverse share split effected on May 28, 2026, and a 1-for-24 reverse share split effected on November 10, 2026, as described in Notes 1(d) and 13 to the Company’s condensed consolidated financial statements included in the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2026.

* Represents an amount less than $1 thousand.

SILEXION THERAPEUTICS CORP
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except share and per share data)

	Nine months ended September 30,		Three months ended September 30,
	2026	2025	2026	2025
OPERATING EXPENSES:
Research and development (including $176 and $0 from related party for the nine-month periods ended September 30, 2026 and 2025, respectively, and $0 from related party for the three-month periods ended September 30, 2026 and 2025)	$4,868	$3,765	$1,286	$2,157
General and administrative (including $298 and $96 from related party for the nine-month periods ended September 30, 2026 and 2025, respectively, and $16 and $38 from related party for the three-month periods ended September 30, 2026 and 2025, respectively)	4,245	3,461	1,398	1,135
TOTAL OPERATING EXPENSES	9,113	7,226	2,684	3,292
OPERATING LOSS	9,113	7,226	2,684	3,292
Financial expenses (income), net (including $(307) and $203 from related party for the nine-month periods ended September 30, 2026 and 2025, respectively, and $(138) and $(26) from related party for the three-month periods ended September 30, 2026 and 2025, respectively)	(296)	271	(151)	(30)
LOSS BEFORE INCOME TAX	$8,817	$7,497	$2,533	$3,262
INCOME TAX	*	3	*	-
NET LOSS	$8,817	$7,500	$2,533	$3,262
LOSS PER SHARE, BASIC AND DILUTED	$115.56	$2,486.20	$13.70	$691.14
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE**	76,305	3,017	184,927	4,720

* Represents an amount less than $1 thousand.

** All share and per share amounts reflect (for periods preceding the relevant reverse share split, on a retroactive basis) the 1-for-10 reverse share split effected on May 28, 2026 and the 1-for-24 reverse share split effected on November 10, 2026, as described in Notes 1(d) and 13 to the Company’s condensed consolidated financial statements included in the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Silexion Therapeutics’ third-quarter 2026 financial results?

Silexion reported a $2.533 million net loss for the three months ended September 30, 2026, versus $3.262 million a year earlier. Research and development expenses were $1.286 million, while general and administrative expenses were $1.398 million.

When did Silexion’s reverse stock split take effect, and what was the ratio?

Silexion effected a 1-for-24 reverse share split on November 10, 2026. Reported share and per-share figures also reflect the earlier 1-for-10 reverse split effected on May 28, 2026.

How is Silexion’s SIL204 Phase 2/3 pancreatic cancer trial designed?

The trial compares SIL204 plus standard-of-care chemotherapy with chemotherapy alone in newly diagnosed, treatment-naïve patients with unresectable Stage 3 locally advanced pancreatic cancer and a confirmed KRAS mutation. The randomized, controlled, multinational, open-label study begins with approximately 18 safety run-in patients, followed by a randomized cohort of approximately 166 patients.

How is SIL204 administered in Silexion’s pancreatic cancer trial?

SIL204 uses a dual-route regimen: ultrasound-guided endoscopic injections directly into the primary tumor, combined with injections under the skin designed to provide systemic exposure.